Literature DB >> 935298

The endogenous--neurotic distinction as a predictor of response to antidepressant drugs.

A Raskin, T H Crook.   

Abstract

An inverse factor analysis of 880 depressed inpatients on 33 endogenous-neurotic variables yielded four patient types. Type 3 resembled the endogenous depressions and Type 2 the neurotic depressions. Type 3 patients responded well to both imipramine and chlorpromazine and did poorly on a placebo. Type 2 patients showed the greatest overall improvement at three weeks irrespective of treatment received, including a placebo.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 935298     DOI: 10.1017/s0033291700007509

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  6 in total

Review 1.  Subtypes of depression--diagnosis and medical management.

Authors:  R J Bielski; R O Friedel
Journal:  West J Med       Date:  1977-05

2.  Are we as depressed as we think we are?

Authors:  D J King; C McMeekin; P C Elmes
Journal:  Ulster Med J       Date:  1977

3.  Prediction of short-term outcome of neurotic-depressive inpatients. Results of an empirical study of 134 inpatients.

Authors:  H J Möller; M Krokenberger; D von Zerssen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

4.  Prediction of therapeutic response in acute treatment with antidepressants. Results of an empirical study involving 159 endogenous depressive inpatients.

Authors:  H J Möller; G Fischer; D von Zerssen
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1987

5.  The place of anxiety in depressive symptomatology.

Authors:  D Widlocher; Y Lecrubier; Y Le Goc
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

6.  Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.

Authors:  Craig H Mallinckrodt; John G Watkin; Chaofeng Liu; Madelaine M Wohlreich; Joel Raskin
Journal:  BMC Psychiatry       Date:  2005-01-04       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.